Brief: FDA Grants Fast Track Status to Corbus Pharma’s Nectin 4 For Head & Neck Squamous Cell Carcinoma Treatment
16/09/2025 13:31
Sept 16 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O: FDA GRANTS FAST TRACK DESIGNATION TO CORBUS PHARMACEUTICALS’ NECTIN-4 TARGETING ADC CRB-701 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA Source text: ID:nGNX8DYVf7 Further company coverage: CRBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study